# Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes

> **NCT01305135** · PHASE1,PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 41 (actual)

## Conditions studied

- High Grade Myelodysplastic Syndrome Lesions

## Interventions

- **DRUG:** azacitidine and idarubicin

## Key facts

- **NCT ID:** NCT01305135
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-30
- **Primary completion:** 2011-06
- **Final completion:** 2016-05-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01305135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01305135, "Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01305135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*